Oncolytics Biotech (ONC) News Today C$1.04 0.00 (0.00%) As of 06/30/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesBuy This Stock ONC Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Oncolytics Biotech Inc.: Oncolytics Biotech Appoints Former Ambrx Executive as Chief Business Officer to Drive Business Development StrategyJune 30 at 6:35 PM | finanznachrichten.deWhy Early-Onset Cancers Are Alarming Researchers—and What It Means for InvestorsJune 30 at 6:35 PM | baystreet.caUSA News Group: The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough?June 26, 2025 | finanznachrichten.deOncolytics Biotech (TSE:ONC) Stock Price Passes Below Two Hundred Day Moving Average - What's Next?June 25, 2025 | marketbeat.comNew Wave of Cancer Treatments Could Change the Game for Patients - and InvestorsJune 24, 2025 | baystreet.caOncolytic virus immunotherapy shows promise in HR+/HER2- breast cancer trialJune 24, 2025 | msn.comOncolytics Biotech (TSE:ONC) Shares Up 10.1% - Still a Buy?June 18, 2025 | marketbeat.comOncolytics Biotech (TSE:ONC) Stock Passes Below 200-Day Moving Average - What's Next?June 17, 2025 | marketbeat.comBig Cuts to U.S. Cancer Research May Create Historic Opening for Biotech InvestorsJune 12, 2025 | baystreet.caEquity Insider: As Public Cancer Funding Wavers, Oncology's Brightest Breakthroughs Are Coming From IndustryJune 12, 2025 | finanznachrichten.deOncolytics Biotech Inc.: Oncolytics Biotech Names New CEO to Accelerate Momentum in Immunotherapy ProgramsJune 11, 2025 | finanznachrichten.deOncolytics Biotech stock takes off after naming new CEOJune 11, 2025 | msn.comOncolytics names Jared Kelly as CEOJune 11, 2025 | msn.comOncolytics Biotech (NASDAQ:ONCY) Stock, Short Interest ReportMay 29, 2025 | benzinga.comInvestor Attention Turns to Biotech as Traditional Cancer Research Models StrainMay 23, 2025 | baystreet.caOncolytics Biotech Q1 2025 Earnings PreviewMay 13, 2025 | msn.com1ONCY : A Look at Oncolytics Biotech's Upcoming Earnings ReportMay 13, 2025 | benzinga.comBuzz on the Bullboards: Energy, cannabis, and Biotech Shine on the TSXApril 17, 2025 | msn.comOncolytics Biotech (TSE:ONC) Sets New 1-Year Low - Here's What HappenedApril 11, 2025 | marketbeat.comSmall-cap cancer therapy innovator raises $20M in flexible fundingApril 11, 2025 | msn.comOncolytics Biotech (TSE:ONC) Hits New 12-Month Low - Here's WhyApril 5, 2025 | marketbeat.comOncolytics Biotech (TSE:ONC) Hits New 1-Year Low - Time to Sell?March 29, 2025 | marketbeat.comOncolytics Biotech Inc.March 24, 2025 | wsj.comOncolytics Biotech (TSE:ONC) Reaches New 12-Month Low - Here's WhyMarch 19, 2025 | marketbeat.comHC Wainwright Has Optimistic View of TSE:ONC FY2026 EarningsMarch 14, 2025 | marketbeat.comLeede Financial Has Positive View of TSE:ONC FY2025 EarningsMarch 14, 2025 | marketbeat.comFY2028 Earnings Forecast for TSE:ONC Issued By HC WainwrightMarch 13, 2025 | marketbeat.comOncolytics Biotech (TSE:ONC) Hits New 1-Year Low - Here's WhyMarch 12, 2025 | marketbeat.comOncolytics Biotech: Continuing To Justify The NegativityMarch 10, 2025 | seekingalpha.comOncolytics price target lowered to C$5 from C$6 at RBC CapitalMarch 10, 2025 | markets.businessinsider.comOncolytics Biotech (TSE:ONC) Stock Price Down 9.3% - What's Next?March 8, 2025 | marketbeat.comOncolytics Biotech Inc.: Oncolytics Biotech Reports Highlights and Financial Results for Q4 and Year-End 2024March 7, 2025 | finanznachrichten.deFrom Clinical Trials to the Market: Cancer Stocks With Big Potential in 2025March 7, 2025 | baystreet.caOncolytics reports Q4 EPS (10c) vs. (5c) last yearMarch 7, 2025 | markets.businessinsider.comOncolytics Biotech (TSE:ONC) Reaches New 12-Month Low - What's Next?March 1, 2025 | marketbeat.comOncolytics Biotech And 2 Other Promising Penny Stocks On The TSXFebruary 7, 2025 | finance.yahoo.comOncolytics Biotech (TSE:ONC) Trading 2.9% Higher - Still a Buy?February 6, 2025 | marketbeat.comFY2029 Earnings Estimate for TSE:ONC Issued By HC WainwrightFebruary 4, 2025 | marketbeat.comOncolytics Biotech (TSE:ONC) Sets New 52-Week Low - Here's WhyFebruary 3, 2025 | marketbeat.comH.C. Wainwright maintains $5 target on Oncolytics Biotech stockFebruary 3, 2025 | msn.comOncolytics Biotech (TSE:ONC) Shares Down 3.4% - Should You Sell?January 17, 2025 | marketbeat.comOncolytics: PEI approves continuation of enrollment in Cohort 5 of GOBLET studyJanuary 16, 2025 | markets.businessinsider.comReplimune's SWOT analysis: biotech firm's stock poised for growth in oncologyJanuary 16, 2025 | msn.comGerman PEI approves enrolment in cohort 5 of Oncolytics’ pancreatic cancer trialJanuary 16, 2025 | finance.yahoo.comOncolytics Biotech (TSE:ONC) Stock Price Down 3.4% - Here's What HappenedJanuary 15, 2025 | marketbeat.comUSA News Group: Cutting-Edge Cancer Therapies Lead the Way into a Transformative YearJanuary 15, 2025 | finanznachrichten.deInvestors Eye Biotech Stocks as Cancer Therapies Take Center Stage in 2025January 15, 2025 | baystreet.caOncolytics Biotech (TSE:ONC) Shares Pass Below 200-Day Moving Average - Here's WhyJanuary 14, 2025 | marketbeat.comOncolytics Biotech: Stocks Undervalued by Analyst Consensus on TSX (ONC)January 4, 2025 | theglobeandmail.comOncolytics Biotech (TSE:ONC) Shares Cross Above 200-Day Moving Average - Here's What HappenedJanuary 4, 2025 | marketbeat.com Get Oncolytics Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for ONC and its competitors with MarketBeat's FREE daily newsletter. Email Address ONC Media Mentions By Week ONC Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ONC News Sentiment▼-0.940.90▲Average Medical News Sentiment ONC News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ONC Articles This Week▼61▲ONC Articles Average Week Get Oncolytics Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for ONC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Fennec Pharmaceuticals News Theratechnologies News Aptose Biosciences News Medicenna Therapeutics News Covalon Technologies News Sernova News Helix BioPharma News Microbix Biosystems News Devonian Health Group News Hemostemix News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (TSE:ONC) was last updated on 7/1/2025 by MarketBeat.com Staff From Our PartnersHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | SponsoredTrump set to Boost Social Security Checks by 400%?If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredFine. Don’t believe me. They called me an alarmist... When in 2010 I said America’s debt was out of control. When I warned it w...Porter & Company | SponsoredGold prediction: $5,000/oz. or higher is comingThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredNvidia’s Huang: AI is going to need 100x more power12Nvidia CEO Jensen Huang didn't mince words. After Nvidia's latest earnings call, Huang said AI now requires...Weiss Ratings | SponsoredTrump Makes Major Crypto AnnouncementTrumps “Secret Weapon” for Crypto Dominance There's a growing push for America to lead the next wave of dig...Crypto 101 Media | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncolytics Biotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncolytics Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
